OncoMatch/Clinical Trials/NCT05572229
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
Is NCT05572229 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Teclistamab and Daratumumab for multiple myeloma.
Treatment: Teclistamab · Daratumumab · Lenalidomide — The primary hypothesis of this study is that teclistamab SC in combination with daratumumab SC or lenalidomide will be safe and induce a high rate of VGPR or better in newly diagnosed multiple myeloma patients This is an open-label, multicenter, non-comparative, 2-cohort, 2-stage with interruption of enrollment for an efficacy and safety interim analysis, interventional Phase 2 study evaluating the efficacy and safety of a combination with Tec-Dara (Cohort A) or Tec-Len (Cohort B) in patients with newly diagnosed multiple myeloma who are not eligible for SCT.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any therapy for multiple myeloma or smoldering myeloma
Exception: short course of corticosteroids prior to signing ICF (not to exceed 40 mg of dexamethasone, or equivalent per day for a maximum of 4 days, total of 160 mg dexamethasone or equivalent)
Any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids prior to signing ICF (not to exceed 40 mg of dexamethasone, or equivalent per day for a maximum of 4 days, total of 160 mg dexamethasone or equivalent).
Cannot have received: radiotherapy
Radiotherapy within 14 days or focal radiation within 7 days.
Cannot have received: corticosteroids
Exception: pretreatment medications excluded
Received a cumulative dose of corticosteroids equivalent to ≥140 mg of prednisone within 14-days before the first dose of study drug (does not include pretreatment medications).
Cannot have received: live, attenuated vaccine
Exception: Non-live or non-replicating vaccines authorized for emergency use (eg, COVID-19) are allowed.
Received a live, attenuated vaccine within 4 weeks before the first dose of study drug. Non-live or non-replicating vaccines authorized for emergency use (eg, COVID-19) are allowed.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify